Hereditary cerebellar atrophy is generally referred to as hereditary ataxia, a group of genetic degenerative diseases characterized by chronic progressive ataxia, which is currently not completely curable.
The etiology and pathogenesis of most hereditary ataxias have not been elucidated, and enzyme deficiencies, biochemical defects, trinucleotide dynamic mutations, mitochondrial function defects, DNA repair function defects, and mutations in ion channel genes have been implicated in the development of the disease.
According to the mode of inheritance, hereditary ataxia can be divided into: (1) autosomal dominant ataxia, such as spinocerebellar ataxia; (2) autosomal recessive ataxia, such as Friedreich’s ataxia; (3) X-linked ataxia; (4) mitochondrial disorders associated with ataxia.
There is a lack of effective treatment. Preventing the birth of affected children and preventing the occurrence of genetic diseases by avoiding consanguineous marriages, promoting genetic counseling, genetic testing of carriers and prenatal diagnosis, and selective abortion are the most fundamental measures.
The principles of treatment for this type of disease include replacement therapy for genetic defects, symptomatic treatment, rehabilitation and surgical correction to improve the patient’s quality of life, and neurotrophic and protective treatments to slow down the progression of the disease. Gene therapy is in the experimental stage and is expected to achieve a cure by replacing, adding or correcting defective genes.
To summarize, there is a lack of effective treatment measures for this disease, mainly to improve the patient’s symptoms as much as possible and slow down the progress of the disease.
It is recommended that patients consult a specialized hospital in a timely manner, control the progression of the disease through active treatment, and actively participate in rehabilitation and brain training.